CGON - CIK 0001991792
The table below shows CG Oncology, Inc.'s income statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of revenue | - | - | - |
| Gross profit | - | - | - |
| R&D | $116.64M | $82.10M | $45.75M |
| SG&A | $73.53M | $33.70M | $9.90M |
| Operating income | -$190.77M | -$114.67M | -$55.45M |
| Income tax | -$270.00K | $1.00K | $1.00K |
| Net income |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$161.00M |
| -$88.04M |
| -$48.61M |
| EPS (diluted) | -$2.08 | -$1.41 | -$15.65 |